Current Report Filing (8-k)
07 Octubre 2021 - 1:25PM
Edgar (US Regulatory)
0001500123
false
Item 9 Labs Corp.
DE
0001500123
2021-10-07
2021-10-07
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report: October 7, 2021
ITEM
9 LABS CORP.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
000-54730
|
|
96-0665018
|
(State of other jurisdiction
|
|
(Commission
|
|
(IRS Employer
|
of incorporation)
|
|
File Number)
|
|
Identification No.)
|
2727
N 3rd Street, Suite
201, Phoenix
AZ
85004
(Address of principal executive offices and zip code)
1-833-867-6337
(Registrant’s
telephone number, including area code)
N/A
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a -12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d -2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e -4(c))
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth
company. ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
|
|
|
|
|
Item 1.01
|
Entry into a Material Definitive Agreement.
|
On October 6, 2021, Item 9 Labs
Corp., a Delaware corporation ("Company"), and Item 9 Labs Colorado LLC. ("Buyer"), entered into an Asset Purchase
Agreement (the "Agreement") with Nebrina Adams County LLC, a Colorado limited liability company ("Seller"),
pursuant to which Purchasing Sub is purchasing certain assets from the Seller. Effective upon the completion of the Sale, the licenses,
lease and certain personal property to operate a licensed recreational marijuana dispensary will be delivered to the Buyer, free and clear
of all liens or encumbrances.. Each of the parties referred to above may be referred to herein as a "Party" and collectively
as the "Parties".
Consideration
(a)
Purchase Price. The total purchase price for the Purchased Assets is Two Million US Dollars
($2,000,000.00 USD) (the "Purchase Price"), payable as follows:
(i) Upon
conditional approvals of the change of ownership from state and local licensing authorities concerning the transfer of ownership of the
Licenses from Seller to Buyer, Buyer shall deposit into an escrow account One Million US Dollars ($1,000,000.00) (the "Initial
Deposit"), by wire transfer in immediately available funds to the bank account designated by the Escrow Agent; and
(ii) At
the Closing, Buyer and Company shall execute and deliver to Seller an unsecured promissory note with a principal amount of Two Hundred
Thousand US Dollars ($200,000.00), with an interest rate of five percent (5%) per annum simple interest, for a term of eighteen (18) full
months commencing on the Closing Date, and payable in six (6) installments commencing on the last day of each three (3) month period following
the Closing Date (the "Note" or "Promissory Note") until paid in full; and (iii) Buyer shall issue
to the Seller Three Hundred Thousand (300,000) shares of PubCo's restricted common shares of the Company. The Shares shall be subject
to a leak out agreement.
Conditions to
the Acquisition
The closing of the
acquisition is contingent upon approval of state and local licensing authorities.
The Company has made customary representations and
warranties in the Agreement. The Agreement also contains customary covenants and agreements, including covenants and agreements relating
to the conduct of the Company's business between the date of the signing of the Agreement and the closing of the transactions contemplated
under the Agreement. The representations and warranties made by the Company are qualified by disclosures made in its disclosure schedules
and Securities and Exchange Commission ("SEC") filings.
A copy of the
Agreement is filed with this Current Report on Form 8-K as Exhibit 2.1 and is incorporated
herein by reference, and the foregoing description of the Agreement is qualified in its entirety by reference thereto.
Section 7 –
Regulation FD
Item 7.01
|
Regulation FD Disclosure.
|
On October 7, 2021,
the Company issued a press release, attached as Exhibit 99.1, announcing the Company entering into the Asset Purchase Agreement. A copy
of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.
The information set forth
in the attached Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of
1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended,
or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01
|
Financial Statements and Exhibits.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
ITEM 9 LABS CORP.
|
|
|
|
Dated: October
7, 2021
|
By:
|
/s/ Robert
Mikkelsen
|
|
|
Robert Mikkelsen
|
|
|
Chief Financial Officer
|
Item 9 Labs (CE) (USOTC:INLB)
Gráfica de Acción Histórica
De Dic 2024 a Ene 2025
Item 9 Labs (CE) (USOTC:INLB)
Gráfica de Acción Histórica
De Ene 2024 a Ene 2025